Upper GI Tract
Article
Co-Diagnosis of Eosinophilic Esophagitis and IBD Increases Disease Burden
Article
Twice- vs Once-Daily PPI Better Suited to Induce Remission in Eosinophilic Esophagitis
News from the FDA/CDC
FDA OKs First Oral Agent for Eosinophilic Esophagitis
Budesonide oral suspension is a corticosteroid indicated for 12 weeks of treatment of EoE in adults and children as young as 11 years.
From the AGA Journals
Gastric cancer screening benefits may vary by country
The benefits of nationwide gastric cancer screening may vary widely between countries.
Latest News
FDA Expands Dupilumab for EoE to Younger Children
EoE drug approval expanded to include children age 1 to 11, following approval in children 12 and older.
Latest News
Etrasimod Appears Effective in Eosinophilic Esophagitis: Phase 2 Study
Among patients given a 1-mg daily dose of etrasimod, there was a 27.4% reduction in peak eosinophil count.
Article
Psychosocial burdens significant in EoE pediatric patients
The New Gastroenterologist
February 2024 – ICYMI